Sign inCreate account

Report workspace tools

NCT06529965RECRUITINGanonymous

Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With Type 2 Diabetes Mellitus: Randomized Controlled Trial

Sponsor

Source record

Gaia AG

Phase

Source record

Not Applicable

Modality

AI-normalized

behavioral intervention

Target

AI-normalized

Digital therapeutic intervention aimed at alleviating diabetes-specific emotional distress through cognitive behavioral therapy (CBT) techniques.

Indication / condition

AI-normalized

Glucose Metabolism Disorders (Including Diabetes Mellitus)

Intervention

Source record

covivio

Source & freshness

Source record

NCT ID

NCT06529965

Original source

ClinicalTrials.gov

Source last updated

Nov 08, 2024

Ingested at

Jun 08, 2026

Internal sync

Jun 08, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06529965

Title

Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With Type 2 Diabetes Mellitus: Randomized Controlled Trial

Sponsor

Gaia AG

Status

RECRUITING

Phase

Not Applicable

Condition raw

Glucose Metabolism Disorders (Including Diabetes Mellitus), Metabolic Disease, Endocrine System Diseases, Diabetes Mellitus, Type 2

Condition normalized

Glucose Metabolism Disorders (Including Diabetes Mellitus), Metabolic Disease, Endocrine System Diseases, Diabetes Mellitus, Type 2

Modality raw

behavioral intervention

Modality normalized

behavioral intervention

Target raw

Digital therapeutic intervention aimed at alleviating diabetes-specific emotional distress through cognitive behavioral therapy (CBT) techniques.

Target normalized

Digital therapeutic intervention aimed at alleviating diabetes-specific emotional distress through cognitive behavioral therapy (CBT) techniques.

Interventions

covivio

Public preview

Source record

Gaia AG's covivio is positioned within the growing digital health market, specifically targeting the management of emotional distress in adults with Type 2 Diabetes Mellitus (T2DM). The trial's focus on emotional well-being complements traditional diabetes management, potentially enhancing patient adherence and overall treatment outcomes. Given the increasing prevalence of T2DM and the associated psychological burden, successful results could lead to significant market opportunities. The competitive landscape includes other digital therapeutics and mental health applications, necessitating a robust differentiation strategy. Diligence should focus on regulatory pathways, reimbursement models, and integration with existing diabetes care frameworks.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With Type 2 Diabetes Mellitus: Randomized Controlled Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06529965

Status

RECRUITING

Phase

Not Applicable

Sponsor

Gaia AG

Executive brief

Investment-Ready Snapshot

Gaia AG's covivio is positioned within the growing digital health market, specifically targeting the management of emotional distress in adults with Type 2 Diabetes Mellitus (T2DM). The trial's focus on emotional well-being complements traditional diabetes management, potentially enhancing patient adherence and overall treatment outcomes. Given the increasing prevalence of T2DM and the associated psychological burden, successful results could lead to significant market opportunities. The competitive landscape includes other digital therapeutics and mental health applications, necessitating a robust differentiation strategy. Diligence should focus on regulatory pathways, reimbursement models, and integration with existing diabetes care frameworks.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 08, 2024
Internal syncJun 08, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06529965

Indication

Glucose Metabolism Disorders (Including Diabetes Mellitus)

Modality

behavioral intervention

Target

Digital therapeutic intervention aimed at alleviating diabetes-specific emotional distress through cognitive behavioral therapy (CBT) techniques.

Intervention

covivio

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.